StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Each factor shows ALGS's percentile within the scored universe — observational ranking, not a recommendation.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $6.39 | $6.21 | -2.82% | 0.1M |
| 05-12 | $6.20 | $6.47 | +4.35% | 0.1M |
| 05-13 | $6.47 | $6.67 | +3.09% | 0.1M |
| 05-14 | $6.64 | $6.69 | +0.75% | 0.2M |
| 05-15 | $6.49 | $5.71 | -12.02% | 0.2M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $9.18M | $2.83M | $2.19M | $2.02M | $1.28M |
Operating Income | Not available | $-26.93M | $-87.98M | $-66.17M | $-37.81M |
Net Income | Not available | $-23.04M | $-24.19M | $-4.31M | $-15.86M |
EPS (Diluted) | $-1.19 | $-2.21 | $-2.45 | $-0.44 | $2.90 |
Total Assets | Not available | $64.56M | $88.53M | $109.76M | $134.71M |
Total Liabilities | Not available | $32.77M | $34.99M | $37.93M | $32.84M |
Cash & Equivalents | Not available | $29.98M | $18.30M | $41.95M | $18.66M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 6.19M | 6.18M | 6.15M | 6.15M |
No sell-side coverage available for ALGS.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Fundamentals not available for ALGS.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.